Daniel Bradbury Sells 7,867 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 7,867 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $29.44, for a total transaction of $231,604.48. Following the transaction, the director now owns 5,700 shares of the company’s stock, valued at approximately $167,808. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Bradbury also recently made the following trade(s):

• On Monday, August 12th, Daniel Bradbury sold 7,883 shares of Castle Biosciences stock. The stock was sold at an average price of $26.65, for a total value of $210,081.95.

Castle Biosciences Stock Down 1.6 %

NASDAQ CSTL opened at $28.30 on Friday. The stock’s 50 day simple moving average is $28.46 and its 200 day simple moving average is $24.06. Castle Biosciences, Inc. has a one year low of $12.07 and a one year high of $32.53. The firm has a market cap of $781.28 million, a PE ratio of -24.55 and a beta of 1.03. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.12 and a quick ratio of 7.92.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Monday, August 5th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of ($0.16) by $0.47. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The business had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $69.95 million. During the same period in the prior year, the firm earned ($0.70) earnings per share. As a group, sell-side analysts forecast that Castle Biosciences, Inc. will post -0.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

Several hedge funds have recently added to or reduced their stakes in CSTL. RiverPark Advisors LLC lifted its position in Castle Biosciences by 362.2% during the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock valued at $63,000 after purchasing an additional 2,242 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Castle Biosciences by 70.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 5,297 shares of the company’s stock worth $117,000 after buying an additional 2,187 shares during the last quarter. Denali Advisors LLC acquired a new position in Castle Biosciences in the first quarter valued at approximately $186,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Castle Biosciences by 10.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock valued at $215,000 after acquiring an additional 952 shares during the last quarter. Finally, Birchview Capital LP bought a new position in Castle Biosciences in the fourth quarter valued at approximately $216,000. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Robert W. Baird upped their price target on Castle Biosciences from $34.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday, August 6th. Stephens restated an “overweight” rating and issued a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, August 6th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $32.80.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.